Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update
16 nov. 2021 09h58 HE
|
Protagenic Therapeutics, Inc.
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
30 août 2021 09h15 HE
|
Protagenic Therapeutics, Inc.
Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic...
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
17 août 2021 07h45 HE
|
Protagenic Therapeutics, Inc.
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
23 juil. 2021 16h21 HE
|
Protagenic Therapeutics, Inc.
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
06 juil. 2021 06h17 HE
|
Protagenic Therapeutics, Inc.
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering
26 avr. 2021 20h58 HE
|
Protagenic Therapeutics, Inc.
New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a...
Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial
16 déc. 2020 09h15 HE
|
Protagenic Therapeutics, Inc.
Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava,...
Three High Profile Publications Support the Potential of Protagenic Therapeutics’s Synthetic TCAP to Treat Stress-Related Psychological Disorders
11 juin 2018 10h15 HE
|
Protagenic Therapeutics, Inc.
Ancient, central role of brain peptide TCAP in maintenance of brain health elucidated in publications in Cell, Nature Communications, and the Journal of Neuro-endocrinology NEW YORK,...